AR115925A1 - Uso de derivados de triptófano y l-metionina para formulación de proteínas - Google Patents
Uso de derivados de triptófano y l-metionina para formulación de proteínasInfo
- Publication number
- AR115925A1 AR115925A1 ARP190102242A ARP190102242A AR115925A1 AR 115925 A1 AR115925 A1 AR 115925A1 AR P190102242 A ARP190102242 A AR P190102242A AR P190102242 A ARP190102242 A AR P190102242A AR 115925 A1 AR115925 A1 AR 115925A1
- Authority
- AR
- Argentina
- Prior art keywords
- tryptophan
- protein formulation
- methionine derivatives
- methionine
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
La presente descripción proporciona métodos y formulaciones que comprenden un polipéptido que comprende residuos de aminoácidos accesibles al solvente susceptibles a la oxidación, en donde se usa N-acetil-DL-triptófano (NAT) y/o L-metionina para evitar la oxidación del polipéptido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862716239P | 2018-08-08 | 2018-08-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR115925A1 true AR115925A1 (es) | 2021-03-10 |
Family
ID=67777405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190102242A AR115925A1 (es) | 2018-08-08 | 2019-08-07 | Uso de derivados de triptófano y l-metionina para formulación de proteínas |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210155715A1 (es) |
EP (1) | EP3833389A1 (es) |
JP (1) | JP2021533149A (es) |
KR (1) | KR20210042936A (es) |
CN (1) | CN112770775A (es) |
AR (1) | AR115925A1 (es) |
AU (1) | AU2019319822A1 (es) |
BR (1) | BR112021002130A2 (es) |
CA (1) | CA3106537A1 (es) |
IL (1) | IL280525A (es) |
MX (1) | MX2021001453A (es) |
SG (1) | SG11202100601TA (es) |
TW (1) | TW202019478A (es) |
WO (1) | WO2020033485A1 (es) |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
AU729039C (en) | 1996-08-30 | 2001-08-02 | Upfront Chromatography A/S | Isolation of immunoglobulins |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
US20080318254A9 (en) | 1997-03-10 | 2008-12-25 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
DE60039596D1 (de) | 1999-03-30 | 2008-09-04 | Japan Tobacco Inc | Verfahren zur herstellung von monoklonalen antikörpern |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2002092017A2 (en) | 2001-05-16 | 2002-11-21 | Albert Einstein College Of Medicine Of Yeshiva University | Human antipneumococcal antibodies from non-human animals |
JP4359503B2 (ja) | 2001-08-23 | 2009-11-04 | ゲンマブ エー/エス | インターロイキン15(il−15)に特異的なヒト抗体 |
CA2513308A1 (en) | 2003-01-17 | 2004-08-05 | Josef Michl | Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
AU2004270103B2 (en) | 2003-05-21 | 2012-02-23 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies against Bacillusanthracis protective antigen |
JP5705115B2 (ja) | 2008-09-10 | 2015-04-22 | ジェネンテック, インコーポレイテッド | 蛋白質の酸化的分解の予防のための組成物および方法 |
ES2617777T5 (es) | 2010-04-23 | 2022-10-13 | Hoffmann La Roche | Producción de proteínas heteromultiméricas |
AR095398A1 (es) * | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones con oxidación reducida |
CN110075293A (zh) | 2013-03-13 | 2019-08-02 | 霍夫曼-拉罗奇有限公司 | 氧化降低的配制剂 |
HUE049707T2 (hu) | 2013-03-13 | 2020-11-30 | Hoffmann La Roche | Csökkent oxidációjú kiszerelések |
CN108430455A (zh) * | 2015-12-30 | 2018-08-21 | 豪夫迈·罗氏有限公司 | 色氨酸衍生物用于蛋白质配制剂的用途 |
-
2019
- 2019-08-07 BR BR112021002130-2A patent/BR112021002130A2/pt unknown
- 2019-08-07 EP EP19759788.3A patent/EP3833389A1/en active Pending
- 2019-08-07 CA CA3106537A patent/CA3106537A1/en active Pending
- 2019-08-07 CN CN201980064230.5A patent/CN112770775A/zh active Pending
- 2019-08-07 KR KR1020217006484A patent/KR20210042936A/ko unknown
- 2019-08-07 AU AU2019319822A patent/AU2019319822A1/en active Pending
- 2019-08-07 SG SG11202100601TA patent/SG11202100601TA/en unknown
- 2019-08-07 WO PCT/US2019/045420 patent/WO2020033485A1/en active Application Filing
- 2019-08-07 JP JP2021506280A patent/JP2021533149A/ja active Pending
- 2019-08-07 TW TW108128028A patent/TW202019478A/zh unknown
- 2019-08-07 AR ARP190102242A patent/AR115925A1/es unknown
- 2019-08-07 MX MX2021001453A patent/MX2021001453A/es unknown
-
2021
- 2021-01-31 IL IL280525A patent/IL280525A/en unknown
- 2021-02-05 US US17/168,621 patent/US20210155715A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202100601TA (en) | 2021-02-25 |
CN112770775A (zh) | 2021-05-07 |
TW202019478A (zh) | 2020-06-01 |
IL280525A (en) | 2021-03-01 |
WO2020033485A1 (en) | 2020-02-13 |
CA3106537A1 (en) | 2020-02-13 |
AU2019319822A1 (en) | 2021-03-18 |
BR112021002130A2 (pt) | 2021-05-04 |
JP2021533149A (ja) | 2021-12-02 |
KR20210042936A (ko) | 2021-04-20 |
US20210155715A1 (en) | 2021-05-27 |
MX2021001453A (es) | 2021-04-12 |
EP3833389A1 (en) | 2021-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020009625A2 (es) | Inhibidor de fap | |
BR112017009405A2 (pt) | composições antibióticas. | |
BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
CO2020009997A2 (es) | Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante | |
ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
EA202090090A1 (ru) | Включение неприродных нуклеотидов и способы с ними | |
BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
MD3880654T2 (ro) | Compuși 2-formil-3-hidroxifeniloximetilici capabili de modularea hemoglobinei | |
PE20200006A1 (es) | Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap | |
EA201892007A1 (ru) | 3-дезоксипроизводное и фармацевтические композиции на его основе | |
MX2017004488A (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
BR112016013832A2 (pt) | Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico | |
BR112016024494A8 (pt) | análogo de peptídeo e seu uso | |
BR112018013071A2 (pt) | uso de derivados de triptofano para formulações de proteínas | |
AR101742A1 (es) | Agonista del receptor de calcitonina y amilina | |
CL2017001592A1 (es) | Complejos radiofarmacéuticos. | |
CY1123040T1 (el) | Συνθεση με βαση αμινοξεα για την αποκατασταση ινο-ελαστινης σε δερματικους συνδετικους ιστους | |
CL2020002797A1 (es) | Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
BR112018011008A2 (pt) | agonistas de cnp de liberação controlada com ligação a npr-c baixa | |
AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
DOP2020000082A (es) | Administración oral de análogos del péptido glp-1 | |
DOP2021000170A (es) | Formulacion de anticuerpos terapeuticos | |
BR112019003816A2 (pt) | composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição | |
EA201591421A1 (ru) | Препараты полипептида фактора ix |